Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

Viking Therapeutics, Inc. (VKTX) closed the latest trading day at $23.91, indicating a -0.99% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.38% ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) saw unusually large options trading on Monday. Stock investors acquired 31,516 call options on the stock. This is an increase of 87% compared ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zentalis Pharmaceuticals (ZNTL – Research ...

NasdaqCM:VKTX Earnings Per Share Growth as at Mar 2025 The latest GPUs need a type of rare earth metal called Terbium and there are only 20 companies in the world exploring or producing it.

Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...

Currently trading with a volume of 1,145,610, the VKTX's price is down by -1.23%, now at $28.0. RSI readings suggest the ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad multi-year manufacturing agreement with CordenPharma for both the oral ...

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Viking Therapeutics (NasdaqCM:VKTX) has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the ...